Lightweight Videoscope Facilitates Urologic Cytoscopy

An advanced digital video-based flexible cystoscope, used in conjunction with its own integrated light source, eliminates the need for a separate camera head, light guide cable, and optical coupler.

The CST-5000 flexible video cystoscope provides vivid images of the internal structures of the bladder, assisting diagnostic and therapeutic procedures with the introduction of one of the world's smallest diameter videoscope insertion tubes, containing a high resolution, miniature charge coupled device (CCD) camera at the
tip of the insertion tube. The videoscope does not contain difficult-to-clean operating channels; instead, it is used in combination with the patented, disposable, sterile slide-on EndoSheath technology that covers the entire scope. The proprietary EndoSheath technology not only isolates the endoscope from the patient, but also contains a disposable operative channel. This prevents instrumentation and patient tissue biopsies from coming in contact with the reusable scope, which in turn eliminates the need for elaborate high-level disinfection between procedures. Rapid equipment turnover, smaller capital investment for additional scope inventory, reduced staff exposure to toxic chemicals, and lower repair and maintenance costs are other advantages of the system. The CST-5000 flexible video cystoscope is a product of Vision-Sciences (Orangeburg, NY, USA).

"Our new digital video cystoscope with the EndoSheath technology is poised to ultimately replace the pervasive old, fiber-optic technology,” said Ron Hadani, Vision-Science CEO. "While gastroenterologists have used costly conventional video endoscopes for years, high conversion costs forced other specialties to use the old 'eye-to-the-eyepiece' fiber-optic technology. This is the first time urologists will have the opportunity to use the world's best videoscope, which is uniquely combined with the practice-efficiency of the EndoSheath technology.”

"With increasing global vigilance on the prevention of hospital acquired infections, we believe our EndoSheath technology offers unique and relevant advantages to multitudes of patients and healthcare practitioners,” said Carlos Babini, Executive Vice President of Vision-Sciences. "We tested this innovative EndoSheath barrier with nano-level scrutiny, and we remain committed to continue research on the clinical efficacy of EndoSheath technology.”

Vision-Sciences has successfully completed viral microorganism barrier testing in for EndoSheath technology, proving that it is effective to microorganisms as small as 27 nanometers – the benchmark level for barriers set by the U.S. Food and Drug Administration (FDA). Dangerous microorganisms such as the AIDS virus (80-120 nanometers), Hepatitis C virus (30-60 nanometers), or Herpes simplex virus (150-200 nanometers) are significantly larger.


Related Links:
Vision-Sciences